BRAF基因与结直肠癌预后的关系

目的：探讨BRAF基因对结直肠癌预后的影响。方法整群收集2011年1月—2013年1月期间在莆田学院附属医院确诊结直肠癌并行结直肠癌根治术的患者153例,其中BRAF基因突变阳性的患者18例(实验组),BRAF基因突变阴性患者135例(对照组),所有患者均具有完整的随访资料。回顾性分析两组的随访资料,总结BRAF基因突变的突变类型,并分析BRAF基因突变阳性对患者预后的影响。结果在该研究中,发现BRAF基因突变型18例(11.8%),其中位于V600E突变15例,占所有突变患者83.3%；位于exon11上的甘氨酸环的突变为3例,占所有突变患者14.3%,未见其他位点突变。 BRAF基因突变多见于近端结肠,而远端结肠及直肠较少见,二者的差异具有统计学意义(P<0.05)。 BRAF基因在肿瘤分化程度、病理浸润深度、淋巴结转移等方面的差异具有统计学意义(P<0.05)。平均随访时间为1~60个月,生存时间为3~60个月,平均生存时间为(35.2±21.5)个月。生存分析实验组的平均生存时间为(19.7±16.8)个月,术后1、2、3、4、5年总生存率分别为61.1%、27.8%、22.2%、5.6%、5.6%。 Log-rank检验显示两组间总生存率的差异有统计学意义(P=0.001)。结论结直肠癌患者癌组织BRAF基因突变率与患者生存率成负相关,提示患者预后不良。

Mutated BRAF Gene Relationship with the Prognosis of Colorectal Cancer

Objective To explore the mutated BRAF gene's influence on the prognosis of colorectal cancer. Methods Group collected in January 2011—January 2013 in putian college affiliated hospital diagnosis of colorectal cancer in parallel, 153 cases of patients with colorectal cancer radical, 18 patients with the mutated BRAF gene mutation positive (experimental group), mutated BRAF gene mutation negative patients, 135 cases (control group), all patients were with complete follow-up data. Two groups of follow-up data were retrospectively analyzed, summarizes the mutated BRAF gene mutation types of mutations, and analyze the mutated BRAF gene mutation positive impact on the prognosis of patients. Results This study, we found the BRAF gene mutation type in 18 cases (11.8%), which is located in the V600E mutation in 15 cases (such as in Figure 2), accounted for all of the mutations were 83.3%; in exon11 glycine loop mutations in 3 cases, accounted for all of the mutations were 14.3%. No other site mutation. BRAF gene mutations were more common in the proximal colon, while the distal colon and rectum were rare, and the differences between the two were statistically significant (P< 0.05). BRAF gene in tumor differentiation, depth of invasion, lymph node metastasis and other aspects of the difference is statistically sig-nificant (P<0.05). Mean follow-up time was 1~60 months, the survival time was 3~60 months, the average survival time was (35.2± 21.5) months. Survival analysis of the experimental group average survival time was (19.7 ± 16.8) months, 1 years, 2 years, 3 years, 4 years, 5 years, the overall survival rate was 61.1%, 27.8%, 22.2%, 5.6%, 5.6%. Log-rank test showed that there was a significant difference in the overall survival rate between the two groups (P= 0.001). Conclusion Patients with colorectal cancer patients with carcinoma tissue BRAF gene mutation rate and survival rate into negative cor-relation, the patient prognosis.